In this issue:
- Nivolumab ±relatlimab in untreated advanced melanoma
- Line-field OCT for actinic keratosis and SCC
- Line-field OCT for in vivo BCC subtype diagnosis
- Adding spartalizumab to dabrafenib-trametinib for BRAF V600 unresectable/ metastatic melanoma
- Cumulative incidence and disease-specific survival of metastatic cutaneous SCC
- FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma
- Patient-led surveillance after treatment of localised melanoma
- Ceralasertib + durvalumab in advanced/metastatic melanoma after failing anti-PD-1 therapy
- Association between melanoma detected during routine skin checks and mortality
- Long-term melanoma brain metastasis outcomes after nivolumab + ipilimumab
Please login below to download this issue (PDF)